[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Royal Cornwall Hospitals Trust\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":135},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,72,96,116],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100641014","ai-assisted-diagnosis-triage-and-assessment-of-hearing-loss-and-tinnitus-100641014",false,"NCT07586098","AI-assisted Diagnosis, Triage and Assessment of Hearing Loss and Tinnitus","Artificial Intelligence for the Automated Diagnosis, Triage, and Assessment of Patients With Hearing Loss and Tinnitus: A Pilot Comparative Study With Clinical Evaluation by Otolaryngologists","Inclusion Criteria:\n\n* Patients assessed in the RCHT virtual hearing loss and tinnitus clinic.\n* Presenting symptoms of hearing loss and\u002For tinnitus.\n* Ability to provide informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Individuals under 18 years of age.\n* Patients unable to provide informed consent.\n* Patients without sufficient English proficiency where translation services cannot be arranged.\n* Cases where data quality is insufficient for analysis.","ALL","18 Years",{"count":19,"type":20},1500,"ESTIMATED","1 Year","OBSERVATIONAL","Hearing loss affects approximately 11 million people in the UK, while tinnitus impacts around 7 million. Both conditions can significantly reduce quality of life and are linked to poorer mental health and employment challenges. Each year, tinnitus alone accounts for more than one million GP appointments, and patients referred to hospital ear, nose and throat (ENT) services often face long delays, sometimes exceeding a year, before their first assessment.\n\nTo address this demand, the Royal Cornwall Hospitals NHS Trust has developed a virtual ENT clinic. Patients undergo a validated hearing test in person and complete online questionnaires. Clinicians then review these data to determine next steps, which may include discharge with advice, referral for imaging, or a face-to-face consultation. Initial trials demonstrated that the majority of patients could be managed virtually, substantially reducing waiting times. However, clinicians must still review every case, limiting capacity for patients who require direct care.\n\nThis project builds on the virtual clinic by introducing artificial intelligence (AI) to support the assessment process. Using explainable AI methods, the system will be trained to replicate clinician-level decision-making while providing transparent reasoning for its recommendations. The study will evaluate how closely AI-generated outcomes align with clinician assessments, with all cases continuing to receive a clinician's final review. Clinicians will not be aware of the recommendations produced by the AI tool, but the study aims to measure how concordant AI recommendations are with clinician assessments.\n\nIf the AI tool's clinical recommendations closely align with clinician recommendations (the gold standard for care), the AI tool could be introduced as a clinical recommendation assistant tool, streamlining the triage and management of hearing loss and tinnitus, enabling clinicians to focus on complex cases, accelerating access to care, and improving efficiency.",[25,26],"Hearing Loss, Adult-Onset","Tinnitus",[28,29,26,30,31,32,33,34,35],"Artificial Intelligence","Hearing Loss","Clinical Decision Support Systems","Computerized","Telemedicine","Otolaryngology","Patient Satisfaction","Feasibility Studies","NOT_YET_RECRUITING","2026-05-07",{"date":39,"type":40},"2026-05-14","ACTUAL",{"date":42,"type":20},"2026-05-30",{"date":44,"type":20},"2027-08-31",{"name":46,"class":47},"Royal Cornwall Hospitals Trust","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":71,"locationsCount":48},"100638678","is-the-1939-cancer-act-fit-for-purpose-in-the-modern-technology-era-100638678","NCT07584824","Is the 1939 Cancer Act Fit for Purpose in the Modern Technology Era?","Inclusion Criteria:\n\nPatients\u002FRelatives:\n\n* UK residents (England and Wales ONLY).\n* Have been treated for a cancer within the last three years.\n* Aged 18 or over.\n* Can complete the survey themselves or have it completed on their behalf by a friend or family member (with the patient's permission).\n\nHealthcare Professionals:\n\n* UK-based professionals in the healthcare industry.\n* Working with patients diagnosed with cancer.\n* Consulting with patients at least once a month or more frequently.\n* Aged 18 or over.\n\nExclusion Criteria:\n\nNo explicit exclusion criteria are defined within provided materials, therefore any individual not meeting the inclusion criteria will be excluded.",true,{"count":57,"type":20},50,"The 1939 Cancer Act in the UK (England \\& Wales) prohibits advertising of cancer treatments to the public, by anyone but the NHS. The rise of the internet and social media presents new challenges to its enforcement and raises questions about unintended consequences for patients being treated for cancer.\n\nThrough anonymous surveys, this study aims to understand how patients, healthcare professionals and industry professionals perceive technological changes and their implications for online and social media cancer care information, as well as highlight opportunities for safe and ethical modernisation.",[60,61,62,63,64],"Cancer","Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment\u002FCare Regimen; i.e. Curative, Life-extending, or Palliative","Cancer (Solid Tumors)","Cancer (With or Without Metastasis)","Cancer (Advanced Stage)","RECRUITING",{"date":67,"type":40},"2026-05-13",{"date":69,"type":40},"2026-01-09",{"date":42,"type":20},{"name":46,"class":47},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":48},"100636551","the-therapeutic-effect-of-expressive-writing-100636551","NCT07567157","The Therapeutic Effect of Expressive Writing.","The Therapeutic Effect of Expressive Writing in People Living With and Beyond Cancer.","Inclusion Criteria:\n\n* To have experienced an internal or external change to their body due to any form of cancer and\u002For its treatment at any point in their lives.\n* To be 18 or older.\n* The ability to read and write in English.\n* To have the ability to provide informed consent.\n\nExclusion Criteria:\n\n* Distress levels that make participation safe or inappropriate due to cancer prognosis or a mental health condition. (This is flagged by the score on the IES questionnaire.)\n* Inability to realistically commit to a 4-week intervention due to poor physical or mental health or other personal commitments.\n* Inability to provide informed consent.",{"count":57,"type":20},"INTERVENTIONAL",[82],"NA","The goal of this clinical trial is to understand the impact of compassionate expressive writing in people living with and beyond cancer. The main question it aims to answer is:\n\nDoes compassionate expressive writing have any impact on well-being outcomes in people living with and beyond cancer, such as body compassion, self-compassion, quality of life and psychological well-being outcomes ?\n\nResearchers will compare compassionate expressive writing with a standard expressive writing task (with no compassionate prompt) to see if there is a difference in self-reported body compassion, self-compassion, quality of life and psychological well-being outcomes between the two conditions.\n\nParticipants will :\n\nComplete a series of pre-intervention questionnaires. Be assigned to one of the two writing conditions. Attend four expressive writing sessions and write freely for approximately 20 minutes in response to a topic related to their cancer experience.\n\nComplete a series of post-intervention questionnaires. Repeat the questionnaires at 1-month follow-up.",[60],[86,87,60],"Self-Compassion","Expressive Writing","2026-04-28",{"date":90,"type":40},"2026-05-05",{"date":92,"type":40},"2025-12-22",{"date":94,"type":20},"2026-05",{"name":46,"class":47},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":48},"100581359","to-perform-a-post-market-study-of-the-performance-of-the-idylla-thyroidprint-assay-using-clinical-samples-in-predicting-the-nature-of-indeterminate-thyroid-nodules-itns-across-multiple-centers-100581359","NCT06849284","To Perform a Post-market Study of the Performance of the Idylla ThyroidPrint Assay Using Clinical Samples in Predicting the Nature of Indeterminate Thyroid Nodules (ITNs) Across Multiple Centers.","Idylla™ ThyroidPrint® RUO Assay Beta-Trial Study","Inclusion Criteria:\n\n* Thyroid nodule ≥1.0 cm\n* With indeterminate cytology\n* Surgery due to be performed\n\nExclusion Criteria:\n\n* Specimens which fail to meet the inclusion criteria.\n* FNA fixed in formalin or transferred in alcohol-based collection buffers which is not according to the protocol instructions.\n* RNA extracts.\n* Patients with ultrasound evidence of malignant cervical adenopathy",{"count":104,"type":20},100,"To perform a post-market study of the performance of the Idylla™ ThyroidPrint® Assay using clinical samples in predicting the nature of indeterminate thyroid nodules (ITNs) across multiple centers.",[107],"Thyroid Cancer","2025-05-29",{"date":110,"type":40},"2025-06-04",{"date":112,"type":40},"2024-12-16",{"date":114,"type":20},"2025-06-30",{"name":46,"class":47},{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":55,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},"100562642","shared-decision-making-and-antimicrobial-stewardship-in-secondary-care-100562642","NCT06605820","Shared Decision-making and Antimicrobial Stewardship in Secondary Care","Shared Decision-making and Antimicrobial Stewardship in Secondary Care: Exploring Opportunities Along the Start Smart Then Focus Patient Pathway","SHARE","Inclusion Criteria:\n\nFor clinicians:\n\n* Participant is willing and able to give informed consent for participation in the study.\n* Senior registrar or consultant medical or surgical doctor working at participating hospitals and caring for inpatients.\n* Fluent in English.\n\nFor patients:\n\n* Participant is willing and able to give informed consent for participation in the study.\n* Male or Female, aged 16 years or above (no upper age limit).\n* Good standard of speaking English and able to read and understand study materials.\n* Received antibiotic for treatment of suspected or confirmed bacterial infection during inpatient stay.\n\nExclusion Criteria:\n\n* For clinicians:\n\n  * Prescribers not currently caring for inpatients\n\nFor patients:\n\n• Patient who received prophylaxis antibiotics only",{"count":57,"type":20},"To identify opportunities for antibiotic prescribing shared decision making between patients and prescribers in secondary care.",[127],"Antibiotic Prescribing is the Study Focus (no Condition)",{"date":110,"type":40},{"date":130,"type":40},"2024-09-03",{"date":132,"type":20},"2025-07",{"name":46,"class":47},2,""]